What coverage agrees on
The reporting broadly agrees that Dr Reddy's and Takeda have signed an agreement for Qdenga in India and that rollout is expected in the first half of 2027.
India · India
Dr Reddy's to distribute Takeda's Qdenga in India
CATCH ME UP
Dr Reddy's Laboratories has entered an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for the Qdenga dengue vaccine.
The deal gives Dr Reddy's exclusive rights in India's private sector for both pediatric and adult patients.
Takeda retains manufacturing, importation, and public market commercialization rights.
The vaccine was approved by the CDSCO in July 2026.
Why it mattersThe deal could widen access to a dengue vaccine in a major market, affecting pricing, rollout timing, and competition.
More context
Availability is expected in the first half of 2027.
The vaccine is administered in two doses and does not require prior screening.
AGREEMENT VS DISAGREEMENT
What lines up. What splits.
A quick read on shared facts, changing details, and different emphasis.
What is changing or disputed
What remains open is the timing of the commercial rollout and how the division of private and public market rights will play out as the vaccine moves toward availability.
HOW COVERAGE DIFFERS
Same story. Different emphasis.
Swipe through the perspectives. Labels describe coverage framing, not truth or quality.
Supportive1
Dr Reddy's Laboratories has secured exclusive rights in India's private sector for Qdenga under the agreement with Takeda. The vaccine is described as approved for pediatric and adult patients, with launch expected in the first half of 2027. One analysis emphasizes that Takeda will keep manufacturing and importation rights while Dr Reddy's handles distribution and marketing. Another notes the two-dose schedule and lack of prior screening.
Distinctive emphasis — reported claim, not independently verified.Sources: scanx.trade
Neutral1
The coverage says Dr Reddy's signed an agreement with Takeda to promote and distribute Qdenga in India. It reports that the vaccine has regulator approval and is expected to be available in the first half of 2027. One account also cites high dengue case counts and says the vaccine is administered in two doses without prior screening. The agreement is presented as a commercial rollout rather than a policy dispute.
1 of 2
STORY TIMELINEHow the coverage developed
The latest eight dated reports, from earliest to newest.
How the coverage developed
FIRST-PARTY STATEMENTS
What the parties are saying
Attributed summaries from official party channels. These are claims, not independent reporting or fact checks.
GO DEEPER
Read the reporting
Scan each source take, then open the original article.
Dr. Reddy's signs exclusive Takeda deal to distribute Qdenga dengue vaccine
Quick source take
Dr Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for the Qdenga dengue vaccine. Announced on September 18, 2026, the deal gives Dr Reddy's exclusive rights in India's private sector for both pediatric and adult patients, while Takeda retains manufacturing, importation, and public market commercialization rights. The vaccine, approved by the CDSCO in July 2026, is anticipated to launch in the first half of 2027.
India’s Dr Reddy’s inks distribution agreement with Takeda for dengue vaccine in India
Quick source take
Dr Reddy's Laboratories announced on Friday that it signed an agreement with Japan's Takeda Pharmaceutical to promote and distribute the Qdenga dengue vaccine in India. The rollout follows the Indian drug regulator's approval of the vaccine for children and adults, with availability expected in the first half of 2027. The World Health Organization noted a high number of global and Indian dengue cases, and Qdenga is administered in two doses without requiring prior screening.